EUCTR2013-001567-24-NL进行中（未招募）不适用
se of individual PK-guided pazopanib dosing: A feasibility study in patients with advanced solid tumors
The Netherlands Cancer Institute Amsterdam, Netherlands0 个研究点开始时间: 2013年5月3日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subjects must provide written informed consent prior to performance of study-specific procedures or assessments and must be willing to comply with treatment and follow up.
- •Note: Procedures conducted as part of the subject’s routine clinical management (e.g., blood count, imaging study such as bone scan) and obtained prior to signing of informed consent may be utilized for screening or baseline purposes provided these procedures are conducted as specified in the protocol;
- •2. Age = 18 years or legal age of consent if greater than 18 years;
- •3. Negative pregnancytest 7 days prior to start dosing;
- •4. Histopathologically confirmed advanced tumors for which pazopanib is considered standard or patients with advanced or metastatic tumors for whom no standard therapy is available;
- •5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
- •6. Evaluable disease according to RECIST 1.1 criteria;
- •7. Adequate organ system function;
- •8. Women of childbearing potential must have a negative serum pregnancy test within 14 days of first dose of study treatment and agree to use effective contraception, as defined in Pregnancy Section in overall Safety Section during the study and for 14 days following the last dose of investigational product.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1. Prior malignancy;
- •2. Central nervous system (CNS) metastases at baseline, with the exception of those subjects who have previously-treated CNS metastases (surgery ± radiotherapy, radiosurgery, or gamma knife) and who meet both of the following criteria: a) are asymptomatic and b) have no requirement for steroids or enzyme-inducing anticonvulsants in prior 4 week interval;
- •3. Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to:
- •4. Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:
- •5.Corrected QT interval (QTc) > 480 msecs
- •6.History of any one or more of the following cardiovascular conditions within the past 6 months:
- •7. Poorly controlled hypertension [defined as systolic blood pressure (SBP) of =140 mmHg or diastolic blood pressure (DBP) of = 90mmHg].
- •Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry. Following antihypertensive medication initiation or adjustment, blood pressure (BP) must be re-assessed three times at approximately 2-minute intervals. At least 24 hours must have elapsed between anti-hypertensive medication initiation or adjustment and BP measurement. These three values should be averaged to obtain the mean diastolic blood pressure and the mean systolic blood pressure. The mean SBP / DBP ratio must be <140/90 mmHg (OR 150/90 mm Hg, if this criterion is approved by Safety Review Team) in order for a subject to be eligible for the study;
- •8. History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.
- •Note: Subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible;
- •9. Major surgery or trauma within 28 days prior to first dose of investigational product and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major surgery);
- •10. Evidence of active bleeding or bleeding diathesis;
- •11. Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that increase the risk of pulmonary hemorrhage
- •12. Recent hemoptysis (>=½ teaspoon of red blood within 8 weeks before first dose of study drug);
- •13. Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject’s safety, provision of informed consent, or compliance to study procedures;
- •14. Unable or unwilling to discontinue use of prohibited medications in for at least 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of the study;
- •15. Treatment with any of the following anti-cancer therapies:
- •radiation therapy, surgery or tumor embolization within 14 days prior to the first dose of pazopanib OR
- •chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of Pazopanib;
- •16. Administration of any non-oncologic investigational drug within 30 days or 5 half lives whichever is longer prior to receiving the first dose of study treatment.
研究者
相似试验
招募中
不适用
se of individual PK-guided pazopanib dosing: A feasibility study in patients with advanced solid tumorscancerNL-OMON40372Antoni van Leeuwenhoek Ziekenhuis30
尚未招募
不适用
PK-guided pazopanib dosing.cancerefficacytoxicitypazopanibkankermaligniteitbijwerkingeneffectpazopanibNL-OMON28938Antoni van Leeuwenhoek, Amsterdam30
已完成
不适用
Personalized therapy for pazopanib by pharmacokinetic analysis in patients with renal cell carcinoma or malignant soft tissue tumorRenal cell carcinoma Malignant soft tissue tumorJPRN-UMIN000034034Tohoku Medical and Pharmaceutical University14
已完成
不适用
se of individual PK-guided sunitinib dosing: A feasibility study in patients with advanced solid tumorsmalignancies10027655cancerNL-OMON34224Antoni van Leeuwenhoek Ziekenhuis30
已完成
不适用
Personalized therapy for pazopanibMalignant soft tissue tumor Renal cell carcinomaJPRN-UMIN000021999Department of pharmaceutical sciences, Tohoku university hospital20